Introduction
Atopic eczema (AE) (atopic dermatitis) is a common, inflammatory skin disorder that adversely affects many aspects of patients' lives. The prevalence of AE among children is 18 .1% in Italy, 20 .6% in Norway, 14.4% in Denmark, and 17.2% in the United States [1] [2] [3] [4] making it one of the most common pediatric skin disease. The International Study of Asthma and Allergies in Childhood (ISAAC) Phase 3 study found that AE prevalence was stabilizing or decreasing in developed countries (New Zealand, Ireland, Sweden, Germany, United Kingdom) but still increasing in developing countries (Mexico, Chile, Kenya, Algeria, and 7 countries in Southeast Asia). 5 AE is also the start of the Atopic March, which is the natural progression of allergies from the skin to the nose and lung. Approximately 30% to 50% of children with AE will develop asthma and 75% will develop allergic rhinitis. 6 Environmental and genetic evidence points to a defect in the skin barrier as a major contributor to the onset of AE and progression of the atopic march. The defect in the epithelial barrier of the skin may in part be due to mutations in the filaggrin gene, a key protein in the formation of the skin barrier. It is now hypothesized that improvement in the skin barrier will prevent the progression of AE to asthma. 7, 8 Clinical presentation of AE AE typically presents in the first years of life with greater than 90% diagnosed in the first 5 years. AE is a clinical diagnosis and not a laboratory or histological diagnosis based on classic criteria of major and minor criteria (Tables 1 and 2 ). The classic distribution of these lesions varies with age: in infancy through early childhood, face, extensor and exposed skin surfaces are involved. In older children, flexural surfaces are more characteristically affected. In adults, the face, neck, chest, hands, and feet areas can also be affected. Other hallmarks include xerosis (dry skin) and pruritus,
Pathogenesis of AE
Although the etiology of the disease is incompletely understood, AE is considered the product of complex interactions among the host's environment, susceptibility genes, skin barrier dysfunction, and local and systemic immune system dysregulation, extensively reviewed by Bieber. 9 Briefly, breakdown of the skin barrier is recognized to be important in the development of AE; however, it is debated whether this event is secondary to the inflammatory response to irritants and allergens ("inside-outside hypothesis") or whether the barrier damage itself drives disease activity ("outside-inside hypothesis"). 10 Clinical data have indicated that the extent of disease activity is correlated with skin barrier function. 11 The skin interaction with the underlying immune system is the next key step in the pathogenesis of AE. For the start of the allergic response in AE, allergen-specific IgE binds to mast cells in the skin through the high-affinity Fc receptor I (FcεRI), resulting in mast-cell degranulation and the release of inflammatory mediators. During this process, the production of IgE by B cells depends on the support of T-helper 2 (Th2) cells. 12 The initial, acute phase of AE is thought to be dominated by Th2 cytokines, whereas the chronic stage is thought to be T-helper 1 (Th1)-dominated; [13] [14] [15] however, there also is evidence that regulatory T (Treg) cells may play a role in the latter stage 16 in the control of the chronic inflammation.
Triggers of AE
Triggers can vary among patients, but commonly include detergents, soaps, toiletries containing alcohol or astringents, assorted chemicals, infectious agents, aeroallergens (eg, dust mites, animal dander), and certain foods. 17 Both food and environmental allergens have been implicated as offending agents in AE, but the incidence is variable among pediatric and adult populations. In adults, less than 2% of AE patients have a food allergy as an exacerbating factor. 18 In contrast, 10% to 33% of severe AE cases have an associated food allergy in infants and young children. 19, 20 The more severe AE is more likely that a food allergy exists and is a contributing factor. Thus, the diagnosis of a food allergy should be considered in young children who have generalized or severe AE, or those who have recalcitrant disease despite aggressive therapy. Milk, soy, egg, peanut, and wheat accounted for 90% of food allergies implicated in AE. 21 Elimination of offending foods can result in clinical improvement of AE. 22 In addition to foods, environmental aeroallergens can also be significant triggers in AE. Aeroallergens may be more important in older children and adults, as these populations are more likely to have become sensitized. More than 85% of adults with AE have evidence of IgE-mediated hypersensitivity to environmental allergens. 23 In children with AE, IgE-mediated aeroallergen sensitization first appears between the ages of 2 to 5 years, and predominates over food allergies by age 5. 24 However, in many patients, aeroallergen sensitization is only relevant for allergic rhinoconjunctivitis and not atopic dermatitis. Nevertheless, in a subset of atopic dermatitis patients inhalational or topical exposures to aeroallergens can exacerbate AE.
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Treatment of AE
The basic treatment of AE is good skin care and avoidance of the allergens, triggers and irritants. Basic skin care involves hydration and moisturization of the skin. The review will focus 
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on the use of anti-inflammatory medication in the treatment of AE. During an acute infection, appropriate antibiotics can be used to treat the infectious trigger. However, the natural history of eczema has intermittent flares with erythema and increased pruritus. The treatment of flares involves the use of anti-inflammatory agents. The classic agent is topical corticosteroids (TCS). TCSs have been the predominant first-line treatment for moderate to severe AE for several decades. 27, 28 The potencies of TCSs range from very mild to very strong, and the choice among formulations is tailored to the severity of the disease and exacerbation and the area of the body that is affected. Cutaneous, potency-related side effects (eg, skin atrophy, striae, telangiectasias, acne rosacea, and perioral dermatitis) limit the long-term use of these agents. 29 However, their long-term application can be problematic in children because of the potential for side effects, particularly skin atrophy and hypothalamic-pituitary-adrenal (HPA)-axis suppression with extensive use of high-potency topical corticosteroids. 30, 31 Another potential problem with TCS is compliance, as many patients and parents express concerns regarding the prolonged use of these agents. 32 Therefore, in the last 10 years, two non-steroidal anti-inflammatory therapies have been developed and approved in the form of two topical calcineurin inhibitorspimecrolimus cream (Elidel ® , SDZ ASM 981; Novartis) and tacrolimus ointment (Protopic ® , FK 506; Astellas Pharma). Pimecrolimus is available as a 1% cream and is approved in the US and Europe for the treatment of mild to moderate AE, in children over 2 years of age; in approximately 40 countries, pimecrolimus is also available for the treatment of infants (3 to 23 months of age). 33 Tacrolimus ointment is approved for the treatment of moderate to severe AE and is available as an ointment in two concentrations: 0.03% and 0.1% for the treatment of adults, and 0.03% for the treatment of children aged 2 to 15 years. 34 Both compounds bind with high affinity to the macrophilin-12 receptor and inhibit calcineurin, a calcium-dependent phosphatase that is required for activation of the nuclear factor of activated T cells (NF-AT). The inactive form of nuclear factor of activated T cells cannot enter the nucleus. Therefore, via blockage of NF-AT, these agents inhibit the inflammatory cascade produced pathologic T cells inhibiting expression of cytokines (IL-2, IL-4, IL-5, IL-10 and interferon-gamma). 35 Pimecrolimus, in addition to preventing expression of pro-inflammatory cytokines and the proliferation of T cells, also inhibits activation of co-receptors required for T-cell activation and prevents the release of inflammatory mediators from mast cells. Unlike TCSs and tacrolimus, pimecrolimus does not induce apoptosis in Langerhans cells. 35, 36 
Clinical evidence
More than 3000 patients were treated with pimecrolimus for up to 2 years in clinical trials. 37, 38 in both adult and pediatric populations. The trials were designed in two basic schemes, one treating acute flares in 6-week double-blind placebocontrol study and the second scheme was the treatment at the first sign of inflammation in a pro-active fashion to prevent acute flares of atopic dermatitis. 39 Improvement in AE was measured by three basic methods, Eczema Area Severity Index (EASI), Investigators' Global Assessment (IGA) and reduction of flares needing topical corticosteroids. The EASI is a validated composite score comprising severity ratings of erythema, oedema/induration/papulation, excoriations and lichenification weighted according to the estimated percentage of affected body surface area (BSA) of each body region. For each body region (head/neck, upper limbs, trunk and lower limbs), an affected area score of 0 to 6 was assigned for the percentage of affected BSA (0% to 100%). The individual ratings for erythema, edema/induration/ papulation, excoriations and lichenification were then added (0 to 3 for each of the four symptoms) before the sum of the individual symptoms (maximum = 12) was multiplied by the affected area score (maximum = 6) to give a maximum of 72. The head/neck subtotal was multiplied by 0.1, the upper limb subtotal by 0.2, the trunk subtotal by 0.3, and the lower limb subtotal by 0.4 before being summed (maximum EASI = 72). 40 The IGA is a physician assigned clinical score that ranges from 0 to 5 (none to very severe) on the physician determination of AE severity.
The pediatric trials have shown short-term efficacy in patients randomized 2:1 to 6 week trial of pimecrolimus treatment or vehicle followed by 20-week open label extension in children young as 3 months of age (Table 3 ). In the trial of 403 children and young adults (aged 1 to 17 years with 35% of the children treated with pimecrolimus were clear or almost clear of AE at 6 weeks, compared 18% children treated with the vehicle (p  0.05). In the same trial, 60% of pimecrolimus-treated patients showed at least a one-point reduction in the IGA score by 6 weeks compared to 33% of vehicle-treated patients. 41 In the infant trial of 186 patients with a baseline IGA score of 2 or 3 (mild or moderate AE), 39 in addition to the other two pimecrolimus-treated patients showed significant improvement in IGA scores compared to placebo at the end of 6 week blinded trial. Similarly in another infant trial, 55% of the pimecrolimus-treated patients were almost or clear (IGA = 1 or 0) compared to 24% in vehicle group. 42 The adult trials were of similar design with 130 adults and open labeled study of 947 of patients from 3 months to 81 years of age (Table 4) . [43] [44] [45] In the adult trial, IGA scores also significantly improved in pimecrolimus group compared to placebo.
Pruritus
One of the clinical features of AE is intense pruritus. AE is often called the itchy skin that rashes. Pimecrolimus cream 1% showed improvement in pruritus by the eighth day in the infant in 70% of the children compared to 37% of the children treated with vehicle (p  0.001). A similar effect was noted in children and adolescents, with 44% of pimecrolimustreated patients reporting no (0) or mild (1) pruritus at Day 8, compared with 26% of vehicle-treated patients (p  0.001). 46 In the adult trial of 130 patients, self-assessed pruritus severity scores had improved by at least 1 point (4-point scale of 0 to 3) in 45% of patients treated with pimecrolimus compared with 17% of those using vehicle (p = 0.0016). 47 A significant treatment effect was also observed shortly after initiating pimecrolimus treatment even in a group of eczema patients with moderate to severe pruritus. Within 2 days, 42% of pimecrolimus-treated compared with 27% of vehicle-treated patients scored their pruritus as mild or absent (pruritus score of 0 or 1; p = 0.040), and these treatment differences were maintained throughout the study. 48 
Erythema/inflammation
The other cardinal features of AE are erythema and inflammation. In one study of moderate AE in the adults, signs and symptoms improved progressively throughout the first 6 weeks of treatment, with a 33% reduction in EASI scores after the first 7 days and eczema score improved by 69.8% at the end of 6 weeks. In comparison, the patients treated with vehicle group had worsening eczema evidenced by an increase by 3.8% after 1 week and at Week 6 at 15.9% (Figure 1) . 47 In the pediatric trials, improvement in eczema severity is also noted by changes in EASI scores. Pimecrolimustreated patients with improvement within 1 week continued to improve during the length of the study (Figure 2) . Young children and adolescents showed improvements for each measure: for example, erythema; 61% of pimecrolimus-treated Treatment of atopic eczema with pimecrolimus Dovepress submit your manuscript | www.dovepress.com Dovepress versus 37% of vehicle-treated at 6 weeks. 41 The improvement in eczema severity occurred in all age groups, including infants. Pimecrolimus reduced the signs of inflammation (erythema and infiltration) by 8 days in the infant trial. 61% of the patients treated with pimecrolimus had no or only mild erythema on all body areas, compared with 27% of patients treated with vehicle (p  0.001). For infiltration, 67% patients treated with pimecrolimus had no or only mild symptoms on all body areas, compared with 40% in the vehicle group in the same infant trial. 42 As mentioned earlier, patients also had short-term improvement in IGA scores. Long-term improvement was noted in a trial of 947 patients in a 1-year open-labeled study, aged from 3 months to 81 years; improvements in IGA were noted by 8 days in the total population. 43, 49 In the same study, 394 patients enrolled with moderate disease; 18% improved to IGA of 0 or 1 by 1 week, rising to 42% at day 168. With a similar study of 262 children with moderate eczema (IGA = 3) at baseline, 34.7% were clear or almost clear of eczema after 1 year of open-labeled treatment. 44 For the 87 children with severe/very severe AE (IGA = 4/5) at baseline, 18.4% were clear or almost clear of AE at 1 year, 19.5% had mild eczema (IGA = 2) and 31% improved to moderate disease (IGA = 3). These results indicate that all patients within varying severity can improve with pimecrolimus treatment.
Prevention of flares
AE is a chronic disease with periods of relapse and flares. Several trials examined the use of pimecrolimus form the start of symptoms to prevent flares in year-long trials in and children and adolescents. The use of pimecrolimus creams decreased over the year in both trials, indicating overall control with pimecrolimus. The total body surface area affected by eczema decreased over a year-long open-label trial from 24% to 7% in children/adolescent trial. 50 The time to first flare was substantial longer in the pimecrolimustreated group compared to the vehicle treated group. In fact, 61% of children and adolescents in the pimecrolimus group were flare-free for 6 months and 51% were flare-free for 12 months of treatment, which is significantly more than the vehicle-treated group, as only 34% of patients in the control group at 6 months and 28% at 12 months were flare-free. 44 For the infants and toddlers, 68% were flare-free for 6 months of treatment, and 57% were flare-free for 12 months of treatment in the pimecrolimus-treated group. In contrast, in the control group, 30% and 28% of patients completed 6 and 12 months of treatment without flares, respectively. 39 In similar studies with pimecrolimus in adults, the prevention of flares can also be observed. In an identical designed trial but of 24 weeks' duration, more adults patients with moderate AE treated with pimecrolimus remained in remission and experienced no major flares compared to vehicle group (pimecrolimus/ vehicle: 59.7% vs 22.1%, p = 0.001).
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Long-term treatment of AE
The alternative strategy to prevent flares is to use medications in a preventative fashion, as in in asthma, another atopic disease. Several recent trials have tried this strategy of medication on a regular basis 2 to 4 times a week to prevent flares even before the start of symptoms. Studies have examined both the use of topical steroids (fluticasone) or tacrolimus ointment three times a week to reduce the incidence of flares (Table 5) . 348 patients (231 children, 117 adults) were randomized at a 2:1 ratio to either intermittent fluticasone propionate (FP) or vehicle, once daily 4 days per week for 4 weeks followed by once daily 2 days per week for 16 weeks. 
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The patients on the active therapy were 7.7 times less likely to have a AE flare. 51 A second trial of similar design examined FP 2 days week compared to placebo for prevention of flares in 295 patients (12 to 65 years of age). The time to first relapse was 6 weeks for placebo compared to 16 weeks for FP. 52 In the Breneman study with tacrolimus three times a week, 197 adult patients were randomized to tacrolimus (125) and vehicle (72). The tacrolimus had more flare-free days (177 for tacrolimus and 134 for vehicle, p = 0.003). Also, the time for first relapse was 169 days for tacrolimus and 43 for vehicle, significantly better for the active therapy (p = 0.037). 53 A similar study in pediatrics showed a significant effect of 105 patients using tacrolimus three times a week compared to placebo after 16-week open-label run-in with 0.03% tacrolimus ointment. The patients on tacrolimus arm had significantly more disease-free days and longer time to first relapse. 54 The third tacrolimus study examined 224 adults randomized to either tacrolimus or placebo twice a week to prevent flares. The active therapy (tacrolimus) increased the time to first flare from 15 to 142 days compared to placebo treatment. 55 The fourth study examined 250 children randomized to either tacrolimus or placebo twice a week to prevent flares. Similar to adult study, the active therapy (tacrolimus) increased the time to first flare from 38 days to 178 days. Also, the number of flares decreased in tacrolimus group compared to placebo.
56
Safety
For the use of any medications, the issue of safety is important (both local and systemic). For topical calcineurin inhibitors, the local side effects would be confined to the skin. During randomized trials using pimecrolimus, the most commonly reported form of application-site reaction in children and adults was a sensation of burning at the application site. Interestingly, it was reported at a similar rate in both vehicleand pimecrolimus-treated children (10.4% of pimecrolimustreated versus 12.5% of vehicle-treated patients). 41 For the systemic side effects, pimecrolimus would need to be absorbed at high levels. However, the use of pimecrolimus cream in AE does not lead to any significant levels in the circulating blood system. In pharmacokinetic studies of children with moderate to severe AE with up to 92% BSA affected, 67% of samples had pimecrolimus blood concentrations below 0.5 ng/mL and 97% of blood concentrations were in the range of 0.5 to 2.0 ng/mL. Also, for rat, pig, and human skin, pimecrolimus demonstrated a 9-to 10-fold lower permeation through skin in vitro than tacrolimus when comparing identical solutions of both compounds. 36 Patients treated with pimecrolimus in the AD trial have normal T and B cell function as evidenced by response to vaccination and delayed hypersensitivity response. Cell-mediated, delayed-type hypersensitivity (DTH) reaction against a range of antigens is a common method of assessing immunocompetence. DTH testing was used to test immune function in one study of pimecrolimus cream 1% with a total of 112 subjects who completed 1 year of treatment (82 pimecrolimus cream 1%; 30 vehicle). 44 Pimecrolimus had no effect on DTH testing with similar response to that of the placebo group.
Skin infections are another concern. Patients with AE are more prone to skin infections: Staphylococcus aureus and viral infections, including herpes simplex, herpes zoster, Epstein-Barr virus, molluscum contagiosum, and human papilloma virus. 57, 58 Skin infections were investigated in 1-year study comparing pimecrolimus and triamcinolone acetonide 0.1% cream in 658 adults. 59 Pimecrolimus was not associated with an increase in bacterial or fungal skin infections, or in herpes simplex or herpes zoster infections compared to triamcinolone. In the pediatric trials, there were no significant differences in overall incidence of skin infections after pimecrolimus treatment in infants or children. In a 2-year open-label trial, the frequency of skin infections did not change over time, as the incidence of skin infections Compared with control treatments, the incidence of all bacterial and viral infections with pimecrolimus in infants treated for more than 1 year was low. 60, 61 Overall, pimecrolimus cream has demonstrated low systemic absorption and a low incidence of systemic adverse events in children and adults.
Pimecrolimus was issued a black box warning in 2006 due to concerns about incidence of lymphoma. This warning was based on hypothetical concerns about pimecrolimus causing Epstein-Barr virus induced lymphoproliferation disease (lymphoma) or skin cancer. This warning was reviewed by many academic allergy and dermatology societies with the feeling that it was not warranted. The joint task force from the American Academy of Allergy Asthma and Immunology and American College of Allergy Asthma and Immunology found that the risk-benefit ratio of topical pimecrolimus and tacrolimus are similar to that of most conventional therapies for the treatment of chronic relapsing eczema. The panel concluded that 1. Lymphoma formation is generally associated with high dose and sustained systemic exposure to pimecrolimus and tacrolimus. 2. The reported cases of lymphoma from topical pimecrolimus and tacrolimus are not consistent with lymphomas observed with systemic immunomodulator therapy. 3. The actual rate of lymphoma formation reported to date for topical calcineurin inhibitors is lower than predicted in the general population. In large-scale pharmacologic database studies of over 250,000 patients, no increase in the incidence with pimecrolimus was noted for lymphoma. 62 The risk of lymphoma does not seem to be an issue for patient using pimecrolimus cream.
Conclusion
Pimecrolimus cream is a safe and effective therapy for the treatment of atopic dermatitis. One of the key components of AE is itch and inflammation. Both elements are relieved within 1 week of pimecrolimus treatment. One of the novel potential uses of pimecrolimus cream in the treatment of AE is the use of proactive therapy. The use of pimecrolimus cream at the first signs and symptoms of AE flare reduces the need for topical steroids. Finally, pimecrolimus cream appears to be safe in both long-and short-term trials with equivalent or superior safety profile to topical corticosteroids.
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